دورية أكاديمية
Comparison of Panitumumab-IRDye800CW and 5-Aminolevulinic Acid to Provide Optical Contrast in a Model of Glioblastoma Multiforme.
| العنوان: | Comparison of Panitumumab-IRDye800CW and 5-Aminolevulinic Acid to Provide Optical Contrast in a Model of Glioblastoma Multiforme. |
|---|---|
| المؤلفون: | Napier TS; Graduate Biomedical Sciences, University of Alabama at Birmingham, Birmingham, Alabama., Udayakumar N; School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama., Jani AH; Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama., Hartman YE; Department of Otolaryngology, University of Alabama at Birmingham, Birmingham, Alabama., Houson HA; Department of Otolaryngology, University of Alabama at Birmingham, Birmingham, Alabama., Moore L; Department of Otolaryngology, University of Alabama at Birmingham, Birmingham, Alabama., Amm HM; Department of Oral and Maxillofacial Surgery, University of Alabama at Birmingham, Birmingham, Alabama., van den Berg NS; Department of Otolaryngology, Stanford University Medical School, Stanford, California., Sorace AG; Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama.; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama., Warram JM; Department of Otolaryngology, University of Alabama at Birmingham, Birmingham, Alabama. mojack@uab.edu.; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama. |
| المصدر: | Molecular cancer therapeutics [Mol Cancer Ther] 2020 Sep; Vol. 19 (9), pp. 1922-1929. Date of Electronic Publication: 2020 Jun 30. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Philadelphia, PA : American Association for Cancer Research, Inc., c2001- |
| مواضيع طبية MeSH: | Aminolevulinic Acid/*therapeutic use , Antineoplastic Agents, Immunological/*therapeutic use , Glioblastoma/*diagnostic imaging , Glioblastoma/*drug therapy , Optical Imaging/*methods , Panitumumab/*therapeutic use , Photosensitizing Agents/*therapeutic use, Aminolevulinic Acid/pharmacology ; Animals ; Antineoplastic Agents, Immunological/pharmacology ; Female ; Humans ; Mice ; Mice, Nude ; Panitumumab/pharmacology ; Photosensitizing Agents/pharmacology |
| مستخلص: | Maximal safe resection of malignant tissue is associated with improved progression-free survival and better response to radiation and chemotherapy for patients with glioblastoma (GBM). 5-Aminolevulinic acid (5-ALA) is the current FDA-approved standard for intraoperative brain tumor visualization. Unfortunately, autofluorescence in diffuse areas and high fluorescence in dense tissues significantly limit discrimination at tumor margins. This study is the first to compare 5-ALA to an investigational new drug, panitumumab-IRDye800CW, in the same animal model. A patient-derived GBM xenograft model was established in 16 nude mice, which later received injections of 5-ALA, panitumumab-IRDye800CW, IRDye800CW, 5-ALA and IRDye800CW, or 5-ALA and panitumumab-IRDye800CW. Brains were prepared for multi-instrument fluorescence imaging, IHC, and quantitative analysis of tumor-to-background ratio (TBR) and tumor margin accuracy. Statistical analysis was compared with Wilcoxon rank-sum or paired t test. Panitumumab-IRDye800CW had a 30% higher comprehensive TBR compared with 5-ALA ( P = 0.0079). SDs for core and margin regions of interest in 5-ALA-treated tissues were significantly higher than those found in panitumumab-IRDye800CW-treated tissues ( P = 0.0240 and P = 0.0284, respectively). Panitumumab-IRDye800CW specificities for tumor core and margin were more than 10% higher than those of 5-ALA. Higher AUC for panitumumab-IRDye800CW indicated strong capability to discriminate between normal and malignant brain tissue when compared with 5-ALA. This work demonstrates that panitumumab-IRDye800CW shows potential as a targeting agent for fluorescence intraoperative detection of GBM. Improved margin definition and surgical resection using panitumumab-IRDye800 has the potential to improve surgical outcomes and survival in patients with GBM compared with 5-ALA. (©2020 American Association for Cancer Research.) |
| References: | Curr Mol Pharmacol. 2012 Jan;5(1):102-14. (PMID: 22122467) Neurosurgery. 2012 Nov;71(5):927-35; discussion 935-6. (PMID: 22895402) Front Oncol. 2017 Dec 22;7:314. (PMID: 29312886) Laryngoscope. 2008 Jun;118(6):1014-8. (PMID: 18520821) Neurosurgery. 2014 Mar;74(3):310-9; discussion 319-20. (PMID: 24335821) Korean J Radiol. 2004 Jan-Mar;5(1):11-8. (PMID: 15064554) Lasers Surg Med. 2008 Oct;40(8):535-42. (PMID: 18798293) Photochem Photobiol. 2010 Nov-Dec;86(6):1373-8. (PMID: 20854414) Theranostics. 2018 Mar 28;8(9):2488-2495. (PMID: 29721094) Cochrane Database Syst Rev. 2014 Jan 28;(1):CD009685. (PMID: 24474579) Neuro Oncol. 2015 Jun;17(6):776-83. (PMID: 25313193) Oncotarget. 2017 Dec 21;9(5):6213-6227. (PMID: 29464066) Lancet Oncol. 2006 May;7(5):392-401. (PMID: 16648043) Photomed Laser Surg. 2013 Sep;31(9):428-33. (PMID: 23869519) Genomics. 1995 Oct 10;29(3):698-703. (PMID: 8575762) Neurosurgery. 2015 Nov;77(5):663-73. (PMID: 26308630) Oper Neurosurg (Hagerstown). 2020 Jan 1;18(1):41-46. (PMID: 31058980) Radiology. 1983 Sep;148(3):839-43. (PMID: 6878708) Lasers Surg Med. 2018 Jul;50(5):399-419. (PMID: 29737540) J Neurosurg. 2020 Jan 24;:1-11. (PMID: 31978877) Neurol Res. 2000 Jun;22(4):361-8. (PMID: 10874685) J Neurosurg. 2020 Feb 21;:1-15. (PMID: 32084631) Oncologist. 2007 May;12(5):577-83. (PMID: 17522246) Biom J. 2008 Jun;50(3):419-30. (PMID: 18435502) J Biomed Opt. 2014;19(7):75002. (PMID: 24996661) Mol Imaging Biol. 2015 Feb;17(1):49-57. (PMID: 25080323) Clin Cancer Res. 2015 Aug 15;21(16):3658-66. (PMID: 25904751) Sci Rep. 2015 Jun 29;5:10169. (PMID: 26120042) Br J Neurosurg. 2015;29(6):850-8. (PMID: 26073144) Front Oncol. 2015 Jan 29;5:5. (PMID: 25688333) J Neurooncol. 2014 Dec;120(3):625-34. (PMID: 25193022) Ann Transl Med. 2015 Jun;3(9):121. (PMID: 26207249) Head Neck. 2012 Jan;34(1):120-6. (PMID: 21284051) Ann Oncol. 2013 Dec;24(12):3117-23. (PMID: 24130262) Medchemcomm. 2014 Sep;5(9):1337-1346. (PMID: 25431648) PLoS One. 2013 May 28;8(5):e63682. (PMID: 23723993) Cell. 2013 Oct 10;155(2):462-77. (PMID: 24120142) Nat Biotechnol. 2007 Oct;25(10):1134-43. (PMID: 17921999) J Neurosurg. 2018 Aug;129(2):341-353. (PMID: 29076783) Br J Radiol. 2015 Sep;88(1053):20150354. (PMID: 26159214) Int J Oncol. 2014 Jul;45(1):302-10. (PMID: 24819299) Lancet Oncol. 2011 Oct;12(11):997-1003. (PMID: 21868284) J Neurosurg. 2000 Dec;93(6):1003-13. (PMID: 11117842) J Neurosurg. 2011 Jul;115(1):3-8. (PMID: 21417701) Ann Surg Oncol. 2012 Nov;19(12):3879-87. (PMID: 22669455) Neurosurg Rev. 2016 Oct;39(4):545-55. (PMID: 26815631) Neurosurgery. 2008 Mar;62(3):564-76; discussion 564-76. (PMID: 18425006) Clin J Oncol Nurs. 2016 Oct 1;20(5 Suppl):S2-8. (PMID: 27668386) Neurosurg Rev. 2015 Oct;38(4):619-28. (PMID: 25736455) Brain Sci. 2017 Dec 20;7(12):. (PMID: 29261148) Acta Neurochir (Wien). 2013 Jun;155(6):965-72; discussion 972. (PMID: 23468036) J Clin Oncol. 2014 Mar 10;32(8):727-8. (PMID: 24516027) Mol Imaging Biol. 2013 Dec;15(6):722-9. (PMID: 23715932) MAbs. 2011 Mar-Apr;3(2):153-60. (PMID: 21150307) |
| معلومات مُعتمدة: | L30 DE025411 United States DE NIDCR NIH HHS; P30 CA013148 United States CA NCI NIH HHS; R00 DE023826 United States DE NIDCR NIH HHS; TL1 TR003106 United States TR NCATS NIH HHS |
| المشرفين على المادة: | 0 (Antineoplastic Agents, Immunological) 0 (Photosensitizing Agents) 6A901E312A (Panitumumab) 88755TAZ87 (Aminolevulinic Acid) |
| تواريخ الأحداث: | Date Created: 20200702 Date Completed: 20201105 Latest Revision: 20210625 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC7483817 |
| DOI: | 10.1158/1535-7163.MCT-19-0819 |
| PMID: | 32606015 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1538-8514 |
|---|---|
| DOI: | 10.1158/1535-7163.MCT-19-0819 |